WOODCLIFF LAKE, NJ, Nov. 20, 2020 (GLOBE NEWSWIRE) -- NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has signed waiver agreements with certain of its existing institutional investors.
Read more here:
Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders
Related Post
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 12th, 2021
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - January 12th, 2021
- GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020 - January 12th, 2021
- Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene - January 12th, 2021
- INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium - January 12th, 2021
- IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant - January 12th, 2021
- Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference - January 12th, 2021
- Generation Bio Announces Closing of Public Offering - January 12th, 2021
- T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus - January 12th, 2021
- Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units - January 12th, 2021
- Qilian International Holding Group Limited Announces Pricing of Initial Public Offering - January 12th, 2021
- Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common... - January 12th, 2021
- Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - January 12th, 2021
- Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study - January 12th, 2021
- Addex to Present at the Baader Helvea Swiss Equities Conference - January 12th, 2021
- iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 - January 12th, 2021
- BetterLife Provides Shareholder Update and 2021 Product Development Roadmap - January 12th, 2021
- Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 - January 12th, 2021
- Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation - January 12th, 2021
- Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities - January 12th, 2021
- Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference - December 11th, 2020
- New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations - December 11th, 2020
- Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain - December 11th, 2020
- Arch Therapeutics to Present at the 13th Annual LD Micro Main Event Conference - December 11th, 2020
- ExCellThera receives Priority Medicines (PRIME) designation from European Medicines Agency for ECT-001 Cell Therapy - December 11th, 2020
- Cynata Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline - December 11th, 2020
- Financial calendar for Zealand Pharma in 2021 - December 11th, 2020
- Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update - December 11th, 2020
- New sales reporting structure introduced. 2020 organic sales growth outlook now expected at 0%, from previously -2% to +2% - December 11th, 2020
- Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors - December 11th, 2020
- Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome - December 11th, 2020
- SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the... - December 11th, 2020
- CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes - December 11th, 2020
- Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion... - December 11th, 2020
- Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress - December 11th, 2020
- AskBio CSO Jude Samulski Named 2020 Business Person of the Year by Triangle Business Journal - December 11th, 2020
- Tauriga Sciences Inc. Commences Development of Vegan, CBD Infused Pet Treat - December 11th, 2020
- Exodus Effect Review - CBD Oil launched – Product Review by Mike Vaughn - December 11th, 2020
- Cronos Group Inc. to Present at the MKM Partners Virtual Conference - December 11th, 2020
- Golden Leaf Holdings Applauds the Historic Passing of the MORE Act - December 11th, 2020
- Centers for Medicare & Medicaid Services Creates New Codes That Establish Specific Payment for Intravascular Lithotripsy Performed Below the Knee - December 5th, 2020
- Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel - December 5th, 2020
- 22nd Century Group to Present at 13th Annual LD Micro Main Event Conference - December 5th, 2020
- Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES) - December 5th, 2020
- Valneva - Déclaration d’actions et de droits de vote – NOVEMBRE 2020 - December 5th, 2020
- Tauriga Sciences Inc. to Further Expand its Product Offerings With Dark Chocolate [20mg] CBD Infused Round Medallions - December 5th, 2020
- Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with... - December 5th, 2020
- Virbac : Declaration of the number of shares and voting rights 11/2020 - December 5th, 2020
- Galapagos increases share capital through subscription right exercises - December 5th, 2020
- Anpac Bio Announces Change of Auditor - December 5th, 2020
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5th, 2020
- Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas - December 5th, 2020
- Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and... - December 5th, 2020
- Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease... - December 5th, 2020
- Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the... - December 5th, 2020
- Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory... - December 5th, 2020
- CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology... - December 5th, 2020
- Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting - December 5th, 2020
- Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic... - December 5th, 2020
- IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting - December 5th, 2020
- BioAge Raises $90M to Treat Aging and Age-related Diseases - December 4th, 2020
- Pandion Therapeutics Appoints Katina Dorton to its Board of Directors - December 4th, 2020
- CytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium - December 4th, 2020
- Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology... - December 4th, 2020
- Syneos Health and ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence and AI to Advance Oncology Research - December 4th, 2020
- Taconic Biosciences Expands Innovative ExpressMODEL® Portfolio - December 4th, 2020
- Parexel Named Best Contract Research Organization by Scrip - December 4th, 2020
- AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19... - December 4th, 2020
- Intrivo Diagnostics Inks National Distribution Agreements with Concordance Healthcare Solutions and NDC for Access Bio CareStart™ COVID-19 Tests - December 4th, 2020
- Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference - December 4th, 2020
- Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal... - December 4th, 2020
- Tauriga Sciences, Inc. Introduces its Product Line of CBD Infused Bath Bombs Under the Tauri-Gum Brand - December 4th, 2020
- Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer - December 4th, 2020
- OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients... - December 4th, 2020
- Issuance of a 4th tranche of €1.5 million of notes convertible into new shares - December 4th, 2020
- Tauriga Sciences Inc. Fully Repays and Retires $88,333.00 Face Value 8.00% Convertible Debenture Issued on May 18, 2020 - December 4th, 2020
- Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs - December 4th, 2020
- Indus Holdings, Inc. Announces Updated Fourth Quarter Guidance - December 4th, 2020
- ERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American... - December 4th, 2020
- BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients - December 4th, 2020